GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Profitability Rank

Accustem Sciences (Accustem Sciences) Profitability Rank : 1 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Profitability Rank?

Accustem Sciences has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Accustem Sciences's Operating Margin % for the quarter that ended in Dec. 2023 was %. As of today, Accustem Sciences's Piotroski F-Score is 9999.


Competitive Comparison of Accustem Sciences's Profitability Rank

For the Biotechnology subindustry, Accustem Sciences's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accustem Sciences's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Profitability Rank falls into.



Accustem Sciences Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Accustem Sciences has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Accustem Sciences's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-0.246 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Accustem Sciences has an F-score of 9999. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Accustem Sciences Profitability Rank Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Accustem Sciences (Accustem Sciences) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5 Penn Plaza, Suite 1954, Floor 19, New York, NY, USA, 10001
Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe. The company takes a holistic view of its role in oncology to empower patients and care team with critical answers and tools and drive innovation in healthcare.